Announcement on submission of the Clinical Trial Plan Notification for phase I clinical trial of Oncolytic virus HF10 against pancreatic cancer in Japan

Kusatsu/Shiga, Japan — Jun 1, 2017 — Takara Bio Inc. (Takara Bio) announced that the Clinical Trial Notification was submitted to PMDA (Pharmaceuticals and Medical Devices Agency; Japanese regulatory agency) to conduct phase I clinical trial of oncolytic virus HF10 (Development code: TBI-1401) as regenerative medicine product in Japan on May 31.
This clinical trial will be conducted in patients with unresectable advanced pancreatic cancer to evaluate safety of HF10 in combination with existing chemotherapeutic drug.
After the clearance, the protocol will be reviewed by each IRB (Institutional Review Board) and the study will be initiated. In this clinical trial, the HF10 manufactured at Center for Gene and Cell Therapy, Takara Bio’s facility, will be used.
Takara Bio is currently conducting clinical trials in patient with unresctable and metastatic melanoma in Japan and US. Based on the results which were obtained so far, the intratumoral injections of HF10 are safe and well-tolerated, and encouraging tumor response was demonstrated. And also, the investigator-initiated clinical research for pancreatic cancer was completed, and the good results were reported*.
* 91th Annual Meeting of the Japan Gastroenterological Endoscopy Society (JGES),May 12, 2016
【Overview of the Clinical Trial】

Study name Phase I Clinical Trial of combination with TBI-1401 (HF10) and gemcitabin plus nab-paclitaxel in patients with unresectable pancreatic cancer
Condition Patients with unresectable advanced pancreatic cancer (Stage III or IV)
Drug Administration method HF10(TB-1401) is intra-tumorally injected under EUS guided
Primary Endpoint Dose Limiting Toxicity
Estimated Enrollment 6 (maximum12)
Duration July 2017 – January 2019
Site National Cancer Research Center East Hospital and other
(2 sites in total)

Regarding domestic development and sales of oncolytic virus HF10, Takara Bio have exclusive licensing agreement with Otsuka Pharmaceutical Co., Ltd., and both companies will consult with each other and aim for the early approval of HF10 in Japan.

For more information:PR・IR Department, Takara Bio Inc.
E-mail: bio-ir@takara-bio.co.jp

This article is translated from press release in Japanese for your convenience.

Forward-Looking Statements
Statements in this news release, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors. Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors’ prices and product strategies, decline in selling power of the Company’s existing and new products, disruptions to production, violations of our intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

return to top